- Previous Close
101.02 - Open
101.16 - Bid 101.58 x --
- Ask 101.58 x --
- Day's Range
100.38 - 101.84 - 52 Week Range
83.65 - 102.72 - Volume
913,877 - Avg. Volume
698,798 - Market Cap (intraday)
200.63B - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
19.72 - EPS (TTM)
5.15 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield 3.50 (3.45%)
- Ex-Dividend Date Mar 11, 2025
- 1y Target Est
--
Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
www.novartis.com75,883
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: NOVNZ.XC
View MorePerformance Overview: NOVNZ.XC
Trailing total returns as of 3/10/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NOVNZ.XC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NOVNZ.XC
View MoreValuation Measures
Market Cap
200.23B
Enterprise Value
215.95B
Trailing P/E
19.72
Forward P/E
14.16
PEG Ratio (5yr expected)
3.46
Price/Sales (ttm)
4.55
Price/Book (mrq)
5.19
Enterprise Value/Revenue
4.76
Enterprise Value/EBITDA
11.88
Financial Highlights
Profitability and Income Statement
Profit Margin
23.09%
Return on Assets (ttm)
10.09%
Return on Equity (ttm)
26.27%
Revenue (ttm)
51.72B
Net Income Avi to Common (ttm)
11.94B
Diluted EPS (ttm)
5.15
Balance Sheet and Cash Flow
Total Cash (mrq)
13.35B
Total Debt/Equity (mrq)
71.16%
Levered Free Cash Flow (ttm)
12.04B